CLS-12311 is under clinical development by Cellerys and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CLS-12311’s likelihood of approval (LoA) and phase transition for Relapsing Remitting Multiple Sclerosis (RRMS) took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 06 Jun 2022 increased CLS-12311’s LoA and PTSR for Secondary Progressive Multiple Sclerosis (SPMS).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CLS-12311 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CLS-12311 overview

CLS-12311 is under development for the treatment of relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis. The cells are administered as intravenous infusion.

Cellerys overview

Cellerys is a biotechnology company focused on the development of CLS12311, a new drug designed for the treatment of multiple sclerosis. Cellerys is headquartered in Zurich, Switzerland.

Quick View CLS-12311 LOA Data

Report Segments
  • Innovator
Drug Name
  • CLS-12311
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.